Torque Therapeutics Stock

torquetx.comHealthcareFounded: 2015Funding to Date: $84.27MM

Developer of an online platform intended to provide immunotherapy services. The company is focused on the specific modulation of immune cell subsets based on novel platform technologies to address intractable cancers, particularly solid tumors, enabling doctors to get new cell therapy cures for cancer.

Register for Details

For more details on financing and valuation for Torque Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Torque Therapeutics.

Register Today


Management Team

Bart Henderson
Co-Founder, President & Board Member
Thomas Andresen Ph.D
Co-Founder and Chief Scientific Officer
Stephen Hodi MD
Scientific Advisory Board Member
Doug Cole MD
John Cox
Chief Executive Officer & Board Member
Douglas Jones
Darrell Irvine Ph.D
Sok Cheng Soh
Chief Financial Officer
Jennifer Camacho JD
Chief Legal Officer
Becker Hewes MD
Chief Medical Officer

Board Members

Doug Cole MD
John Dineen
Douglas Lauffenburger Ph.D
John Cox
Bart Henderson
John Hohneker MD

Other companies like Torque Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Torque Therapeutics, a clinical stage, product-platform company developing proprietary, first-in-class Deep Primedâ„¢ adoptive cell transfer therapeutic
Genetic engineering a patient’s own immune cells to make them better cancer fighters is the latest tool in oncology, following FDA approvals of two such